Compare SKLZ & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKLZ | TIL |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.0M | 74.7M |
| IPO Year | N/A | 2021 |
| Metric | SKLZ | TIL |
|---|---|---|
| Price | $4.49 | $7.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $14.00 | ★ $125.00 |
| AVG Volume (30 Days) | 71.8K | ★ 257.8K |
| Earning Date | 11-06-2025 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $92,256,000.00 | N/A |
| Revenue This Year | $13.33 | N/A |
| Revenue Next Year | $12.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.54 | $5.67 |
| 52 Week High | $9.11 | $42.79 |
| Indicator | SKLZ | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 42.58 | 31.51 |
| Support Level | $4.23 | $6.91 |
| Resistance Level | $4.56 | $7.31 |
| Average True Range (ATR) | 0.21 | 0.65 |
| MACD | 0.05 | -0.15 |
| Stochastic Oscillator | 69.77 | 20.24 |
Skillz Inc is a two-sided mobile gaming platform that connects developers with competitive players. The company's reportable business segments are: the Skillz segment and the Aarki segment. Skillz segment's highlights include Monetize Through Competitions, Player Matching, Cross-Platform Support, Comprehensive Analytics, and Focus on Game Development. Aarki is an artificial intelligence company that delivers advertising solutions. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The majority of its revenue is generated from the Skillz segment. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.